Tesaro (Tesaro) ROCE % : -82.73% (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Tesaro ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tesaro's annualized ROCE % for the quarter that ended in Sep. 2018 was -82.73%.

Tesaro ROCE % Historical Data

The historical data trend for Tesaro's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tesaro ROCE % Chart

Tesaro Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

ROCE %

Get a 7-Day Free Trial

-77.42

-93.46

-109.50

-78.21

-65.12

Tesaro Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
ROCE %	Get a 7-Day Free Trial															-17.23	-106.08	-95.25	-103.18	-82.73

Tesaro ROCE % Calculation

Tesaro's annualized ROCE % for the fiscal year that ended in Dec. 2017 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2017 )		(A: Dec. 2016 )		(A: Dec. 2017 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2017 )		(A: Dec. 2016 )		(A: Dec. 2017 )
	=	-475.044	/	( ( (839.845 - 76.773)	+	(862.185 - 166.206) )	/ 2 )
	=	-475.044	/	( (763.072	+	695.979)	/ 2 )
	=	-475.044	/	729.5255
	=	-65.12 %

Tesaro's ROCE % of for the quarter that ended in Sep. 2018 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2018 )		(Q: Jun. 2018 )		(Q: Sep. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2018 )		(Q: Jun. 2018 )		(Q: Sep. 2018 )
	=	-474.348	/	( ( (810.453 - 184.18)	+	(710.84 - 190.442) )	/ 2 )
	=	-474.348	/	( ( 626.273	+	520.398 )	/ 2 )
	=	-474.348	/	573.3355
	=	-82.73 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2018) EBIT data.

Tesaro (NAS:TSRO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tesaro ROCE % Related Terms

Thank you for viewing the detailed overview of Tesaro's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tesaro (Tesaro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tesaro Inc (NAS:TSRO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.tesarobio.com

Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.

Executives

Mary Lynne Hedley	director, officer: President & COO	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Kavita Patel	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Huber Martin H. Jr.	officer: SVP & Chief Medical Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Moulder Leon O Jr	director, officer: Chief Executive Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Timothy R Pearson	officer: Exec. VP, CFO	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Grant C. Bogle	officer: Sr. VP, Chief Commercial Ofc	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Collier Earl M Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Beth C Seidenberg	director
Joseph L Farmer	officer: Sr VP, Gen Counsel & Secretary	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Patrick J Kerins	10 percent owner